Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 7
2011 2
2013 1
2014 3
2015 1
2017 1
2018 2
2019 1
2021 4
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Oseltamivir in pregnancy and birth outcomes.
Ehrenstein V, Kristensen NR, Monz BU, Clinch B, Kenwright A, Sørensen HT. Ehrenstein V, et al. BMC Infect Dis. 2018 Oct 16;18(1):519. doi: 10.1186/s12879-018-3423-z. BMC Infect Dis. 2018. PMID: 30326840 Free PMC article.
We examined the association between oseltamivir use during pregnancy and birth outcomes. METHODS: This was a nationwide registry-based prevalence study with individual level data linkage, in a setting of universal health care access. We included all re …
We examined the association between oseltamivir use during pregnancy and birth outcomes. METHODS: This was a nat …
Maternal and Perinatal Outcomes of Influenza in Pregnancy after Treatment with Oseltamivir.
Abraham K, Abraham A, Regi A, Lionel J, Thomas E, Vijayaselvi R, Jeyaseelan L, Abraham AM, Santhanam S, Kuruvilla KA, Steinhoff MC. Abraham K, et al. J Glob Infect Dis. 2021 Jan 29;13(1):20-26. doi: 10.4103/jgid.jgid_157_20. eCollection 2021 Jan-Mar. J Glob Infect Dis. 2021. PMID: 33911448 Free PMC article.
Gestational age-matched asymptomatic controls formed Cohort 3. Women in Cohort 1 received oseltamivir for 5 days. The incidence of small-for-gestational age (SGA) and preterm birth were the primary outcomes. ...Secondary maternal and neonatal outcomes …
Gestational age-matched asymptomatic controls formed Cohort 3. Women in Cohort 1 received oseltamivir for 5 days. The incidence of sm …
Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants.
Chambers CD, Johnson D, Xu R, Luo Y, Jones KL; OTIS Collaborative Research Group. Chambers CD, et al. Birth Defects Res. 2019 Nov 15;111(19):1487-1493. doi: 10.1002/bdr2.1566. Epub 2019 Aug 8. Birth Defects Res. 2019. PMID: 31397112
BACKGROUND: Influenza infection during pregnancy increases risks for adverse outcomes for both mother and fetus. ...Crude relative risks (RRs) or hazard ratios (HRs) were estimated together with 95% confidence intervals (CIs) for these outcomes. RESULTS: Ther …
BACKGROUND: Influenza infection during pregnancy increases risks for adverse outcomes for both mother and fetus. ...Crude rela …
Safety of oseltamivir in pregnancy: a review of preclinical and clinical data.
Donner B, Niranjan V, Hoffmann G. Donner B, et al. Drug Saf. 2010 Aug 1;33(8):631-42. doi: 10.2165/11536370-000000000-00000. Drug Saf. 2010. PMID: 20635821 Review.
This article reviews pre-clinical and clinical data to assess the safety of oseltamivir administered during pregnancy, in the context of the effects of influenza on adverse pregnancy outcomes and fetal malformations. ...Fetal outcomes were known …
This article reviews pre-clinical and clinical data to assess the safety of oseltamivir administered during pregnancy, in the …
The safety of oseltamivir in pregnancy: an updated review of post-marketing data.
Wollenhaupt M, Chandrasekaran A, Tomianovic D. Wollenhaupt M, et al. Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1035-42. doi: 10.1002/pds.3673. Epub 2014 Jul 4. Pharmacoepidemiol Drug Saf. 2014. PMID: 24995623 Review.
RESULTS: Of the 2926 maternal exposures to oseltamivir retrieved from the Safety Database, pregnancy outcomes were known for 2128 women. ...CONCLUSIONS: The data reviewed in this article reinforce the findings of a previous review, suggesting that oseltami …
RESULTS: Of the 2926 maternal exposures to oseltamivir retrieved from the Safety Database, pregnancy outcomes were know …
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Svensson T, Granath F, Stephansson O, Kieler H. Svensson T, et al. Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1030-4. doi: 10.1002/pds.2194. Epub 2011 Jul 19. Pharmacoepidemiol Drug Saf. 2011. PMID: 21774030
PURPOSE: To compare birth outcomes between women exposed and unexposed to the antiviral medications oseltamivir or zanamivir during pregnancy. ...None of the women exposed to oseltamivir or zanamivir had been admitted to hospital for influenza d …
PURPOSE: To compare birth outcomes between women exposed and unexposed to the antiviral medications oseltamivir or zana …
Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.
Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Håberg SE, Mølgaard-Nielsen D, Pasternak B, Kieler H. Graner S, et al. BMJ. 2017 Feb 28;356:j629. doi: 10.1136/bmj.j629. BMJ. 2017. PMID: 28246106 Free PMC article.
Infants were defined as exposed if the women filled a prescription during pregnancy for either of the two neuraminidase inhibitors oseltamivir or zanamivir.Main outcomes Low birth weight, low Apgar score, preterm birth, small for gestational age …
Infants were defined as exposed if the women filled a prescription during pregnancy for either of the two neuraminidase inhibitors …
Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 Influenza A.
Oluyomi-Obi T, Avery L, Schneider C, Kumar A, Lapinsky S, Menticoglou S, Zarychanski R. Oluyomi-Obi T, et al. J Obstet Gynaecol Can. 2010 May;32(5):443-447. doi: 10.1016/S1701-2163(16)34497-8. J Obstet Gynaecol Can. 2010. PMID: 20500952
These patients frequently required non-conventional ventilatory support such as high frequency ventilation or extracorporeal membrane oxygenation (ECMO). All patients received oseltamivir. Two patients died while in the ICU. Three of six patients had adverse perinatal o …
These patients frequently required non-conventional ventilatory support such as high frequency ventilation or extracorporeal membrane oxygen …
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta-analysis of cohort studies.
Lian J, Adilijiang M, Chang C, Jiang H, Zhang Y. Lian J, et al. Br J Clin Pharmacol. 2022 Mar;88(3):911-918. doi: 10.1111/bcp.15033. Epub 2021 Sep 2. Br J Clin Pharmacol. 2022. PMID: 34378216 Free article. Review.
RESULTS: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase-inhibitor medication during pregnancy were included. ...Further analyses limited to oseltamivir exposure were consistent with the overall results. …
RESULTS: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase-inhibitor medication …
Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System.
Schatz M, Chambers CD, Jones KL, Louik C, Mitchell AA. Schatz M, et al. Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S64-8. doi: 10.1016/j.ajog.2011.01.047. Epub 2011 Feb 18. Am J Obstet Gynecol. 2011. PMID: 21333964
The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) has been designed to assess systematically the safety of vaccines and medications during pregnancy and is suited ideally to evaluate the gestational safety of seasonal and pandemic influenza vacc …
The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) has been designed to assess systematically the safety of vacci …
24 results